SCYX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 09:32):

Stats
Today's Volume	8 237.00
Average Volume	200 896
Market Cap	56.25M
EPS	$-0.390 ( 2024-03-29 )
Next earnings date	( $-0.180 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	1.070
ATR14	$0.00500 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Sukenick Scott	Sell	15 179	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	290 590	Common Stock
2024-01-26	Angulo Gonzalez David	Buy	431 030	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	215 515	Employee Stock Option (Right to Buy)
2024-01-26	Macleod Ivor	Buy	143 675	Common Stock

INSIDER POWER
98.26
Last 93 transactions
Buy: 4 299 100 \| Sell: 614 179

Volume Correlation

Long: -0.13 (neutral)

Short: 0.44 (neutral)

Signal:(58.967) Neutral

SCYNEXIS Inc Correlation

10 Most Positive Correlations
XELA	0.888
ZSAN	0.887
QLGN	0.874
SWVL	0.874
KTTA	0.866
SMIT	0.858
LGMK	0.858
XFOR	0.855
QAT	0.854
NVAX	0.853

10 Most Negative Correlations
CROX	-0.88
AVAC	-0.874
FNVT	-0.872
GDNR	-0.871
BTWN	-0.87
XENT	-0.869
MLVF	-0.866
ADAL	-0.864
CNGL	-0.863
HWCC	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SCYNEXIS Inc Correlation - Currency/Commodity

0.16
( neutral )

0.15
( neutral )

0.00
( neutral )

-0.07
( neutral )

SCYNEXIS Inc Financials

Annual	2023
Revenue:	$140.14M
Gross Profit:	$123.71M (88.27 %)
EPS:	$1.400

Q4	2023
Revenue:	$5.80M
Gross Profit:	$-9.02M (-155.53 %)
EPS:	$-0.530

Q3	2023
Revenue:	$1.76M
Gross Profit:	$1.38M (78.48 %)
EPS:	$-0.0367

Q2	2023
Revenue:	$131.45M
Gross Profit:	$131.03M (99.68 %)
EPS:	$2.56

Financial Reports:

No articles found.

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.